Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Inclusion Criteria

• 12 < 18 years of age
• Previously treated or untreated, unresectable Stage III or Stage IV malignant melanoma
• Karnofsky Performance Status (KPS) or Lansky Score ≥ 50

Exclusion Criteria

• Primary Ocular Melanoma
• Prior therapy with a Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) or Programmed death- 1 (PD-1) antagonist, or Programmed cell death- ligand 1 (PD-L1) or CD137 agonists
• Symptomatic brain metastases
• History of autoimmune diseases